Repair Biotechnologies Competitors and Similar CompaniesClear all

Nouscom's competitors and similar companies include StrideBio, Lacerta Therapeutics and Dyne Therapeutics.
Nouscom
Nouscom
Nouscom is a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.
StrideBio
StrideBio
StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral vector technologies and therapeutics for rare diseases.
Lacerta Therapeutics
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company.
Dyne Therapeutics
Dyne Therapeutics
Dyne Therapeutics is a biotechnology company which is engaged in the development of targeted therapies for patients with serious muscle diseases.
Founding Date
Founding Date
2015
Founding Date
2015
Founding Date
2017
Founding Date
2018
Type
Type
Private
Type
Private
Type
Private
Type
Public
Tags
Locations
Locations
Basel, CH HQ
Roma, IT
Locations
US HQ
Locations
Alachua, US HQ
Alachua, US
Locations
Waltham, US HQ
Employees
Employees
633% increase
Employees
5
Employees
13
Employees
1451% decrease

Funding

Latest funding round
Latest funding round
$ 49m (over 8 years ago)
Latest funding round
$ 81.5m (over 5 years ago)
Latest funding round
$ 30m (almost 8 years ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 62.6m
Total funding raised
$ 97.2m
Total funding raised
$ 30m
Total funding raised
$ 165m
For sources of this data, please see the company profile

View Company Profiles

StrideBio
HQ
US
Employees
5

StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral vector technologies and therapeutics for rare diseases.

View company
Lacerta Therapeutics
HQ
Alachua, US
Employees
13

Lacerta Therapeutics is a clinical stage gene therapy company.

View company
Dyne Therapeutics
HQ
Waltham, US
Employees
145↓ 1% decrease

Dyne Therapeutics is a biotechnology company which is engaged in the development of targeted therapies for patients with serious muscle diseases.

View company